登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Complement C5a】

Complement C5a信息

英文名称:Complement C5a
中文名称:补体C5a
靶点别称:C5a Complement,Complement 5a,Complement Component 5a
上市药物数量:0
临床药物数量:3
最高研发阶段:临床三期

Complement C5a产品列表

ACRO质量管理体系
 
评论(2)
C5A-H5116|Human Complement C5a Protein, Tag Free
  1. 176XXXXXXX3
  2. 2人赞
  3. 因为实验室用的蛋白种类比较多,所以Acro,Sino,R&D的产品都有在用,因为Acro到货最快,所以一直都是我们的第一选择,产品质量也很赞。但有时候做实验也会发现不同厂家的产品会有差异,同样的氨基酸序列,同样的浓度,很想咨询一下这种差异来源是什么呢?每次实验前买好几种产品真的很麻烦 ̄□ ̄||
  4. 2020-07-01
C5A-H5116|Human Complement C5a Protein, Tag Free
  1. 151XXXXXXX5
  2. 2人赞
  3. 从Acro订购太多蛋白了,这一款给我印象深刻,不说试用装很大方地送我做预实验,我所需的蛋白他们还会开发不同种属的,节省了我很多时间,最重要的,相关蛋白,他家不止做结合实验,还会把相关活性实验也进行检测,而且还分享给客户,那是相当周全了。愿所有的蛋白你家都有。
  4. 2019-09-26
 

Complement C5a分子别名

C5a,Complement Component 5a

Complement C5a分子背景

Complement Component C5a (C5a) is also known as C5,and is a protein fragment released from complement component C5.,is a potent chemotactic factor for human peripheral blood neutrophils and monocytes, and is believed to play an important role in a number of inflammatory conditions. There are several functions in the below: C5a is an anaphylatoxin, causing the release of histamine from mast cells; C5a is effective leukocyte chemoattractants, causing the accumulation of white blood cells, especially neutrophil granulocytes, at sites of complement activation; C5a activates white blood cells by increasing avidity for white blood cell integrins and upregulating the Lipoxygenase pathway for arachidonic acid metabolism; C5a is a powerful inflammatory mediator, and seems to be a key factor in the development of pathology of many inflammatory diseases involving the complement system; C5a modulates balance between activating versus inhibitory IgG Fc receptors on leukocytes, thereby enhancing autoimmune response.

Complement C5a临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Vilobelimab CaCP-29; IFX-1 临床三期 Inflarx Nv 韦格纳肉芽肿, 感染性休克, 抗中性粒细胞胞浆抗体相关性血管炎, 药物相关的副作用和不良反应, 显微镜下多血管炎, 坏疽性脓皮病, 脓毒病, 新型冠状病毒感染, 间质性肺疾病, 化脓性汗腺炎, 全身炎症反应综合征 详情
BDB-001 BDB-1; BDB-001; BDB001; BDB 001 临床三期 舒泰神(北京)生物制药股份有限公司 抗中性粒细胞胞浆抗体相关性血管炎, 新型冠状病毒感染, 化脓性汗腺炎 详情
STSA-1002 STSA-1002; STSA1002 临床二期 舒泰神(北京)生物制药股份有限公司 抗中性粒细胞胞浆抗体相关性血管炎, 新型冠状病毒感染, 成人呼吸窘迫综合征 详情

消息提示

请输入您的联系方式,再点击提交!

确定